ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial.

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84

Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50

TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. BMC Cancer (2016) 1.38

Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24

High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release (2008) 1.19

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Development of therapeutic HPV vaccines. Lancet Oncol (2009) 1.04

Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol (2015) 0.98

Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96

Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96

Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96

Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol (2008) 0.94

Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother (2013) 0.94

Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90

Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach. Open Virol J (2012) 0.89

Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89

DNA vaccines for cervical cancer. Am J Transl Res (2010) 0.88

Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87

Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86

Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother (2016) 0.82

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther (2014) 0.81

Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80

Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One (2014) 0.80

Viruses and human cancer. Yale J Biol Med (2006) 0.80

Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol Oncol (2014) 0.78

Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78

Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications. Microb Cell Fact (2016) 0.77

Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater (2008) 0.76

Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology (Williston Park) (2016) 0.75

Medical treatment of cervical intraepithelial neoplasia II, III: an update review. Int J Clin Oncol (2009) 0.75

p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68

An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med (2007) 4.10

p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41

Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15

Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00

Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer (2014) 2.74

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50

Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 2.42

Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol (2010) 2.16

The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol (2004) 2.09

Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08

Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol (2002) 2.02

Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol (2005) 1.97

Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev (2002) 1.97

Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88

NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res (2002) 1.88

Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol (2010) 1.80

Alveolarization continues during childhood and adolescence: new evidence from helium-3 magnetic resonance. Am J Respir Crit Care Med (2011) 1.78

Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70

The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70

Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res (2012) 1.68

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66

Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer (2009) 1.65

A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica (2010) 1.63

Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol (2009) 1.62

Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol (2007) 1.60

Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer (2009) 1.59

HPV testing. Visible expectations and hidden realities. Am J Clin Pathol (2003) 1.59

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol (2008) 1.54

Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol (2004) 1.54

Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53

Abnormal cervical screen follow-up among low-income Latinas: Project SAFe. J Womens Health Gend Based Med (2002) 1.53

A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53

Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol (2005) 1.52

Transitional B cells: step by step towards immune competence. Trends Immunol (2003) 1.50

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48

Vulvar cancer in young women: demographic features and outcome evaluation. Am J Obstet Gynecol (2009) 1.48

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol (2008) 1.47

Breastfeeding and lung function at school age: does maternal asthma modify the effect? Am J Respir Crit Care Med (2012) 1.47

Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol (2012) 1.46

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42

Balancing efficacy and safety in the use of oral sedation in dental outpatients. J Am Dent Assoc (2006) 1.42

Causal links between RSV infection and asthma: no clear answers to an old question. Am J Respir Crit Care Med (2009) 1.42

Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One (2012) 1.42

Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine (2005) 1.40

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol (2003) 1.40

Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio (2012) 1.36

Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature (2005) 1.36

Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance. Am J Respir Crit Care Med (2013) 1.35

Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol (2009) 1.27

Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol (2010) 1.26

Spectroscopic diagnosis and imaging of invisible pre-cancer. Faraday Discuss (2004) 1.25

Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol (2008) 1.25

p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.24

Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol (2007) 1.23

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) (2011) 1.23

Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. Eur J Hum Genet (2008) 1.23

Do-it-yourself (DIY) pathology. Nat Biotechnol (2008) 1.23

Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol (2006) 1.22

Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol (2003) 1.21

Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer (2012) 1.21

Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res (2008) 1.21

Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol (2003) 1.20

Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol (2005) 1.19

Neural substrates of the interaction of emotional stimulus processing and motor inhibitory control: an emotional linguistic go/no-go fMRI study. Neuroimage (2007) 1.19

Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol (2004) 1.17

Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol (2009) 1.16

Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol (2007) 1.16

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15

Association between reported exposure to road traffic and respiratory symptoms in children: evidence of bias. Int J Epidemiol (2006) 1.14

Influenza-related hospitalizations among young children in Leicestershire. Pediatr Infect Dis J (2003) 1.12

Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol (2010) 1.11

Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol (2004) 1.10

Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception (2007) 1.09

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09

Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. J Allergy Clin Immunol (2011) 1.08

Scrotal emergencies. Emerg Med Clin North Am (2011) 1.08

BMP4-directed trophoblast differentiation of human embryonic stem cells is mediated through a ΔNp63+ cytotrophoblast stem cell state. Development (2013) 1.07

The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol (2012) 1.07

Cohort profile: the Leicester respiratory cohorts. Int J Epidemiol (2007) 1.06

Computed tomography scan utilization in emergency departments: a multi-state analysis. J Emerg Med (2010) 1.05

BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol (2007) 1.05

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J (2010) 1.04

Cloning and Gene Replacement Mutagenesis of a Pseudomonas atlantica Agarase Gene. Appl Environ Microbiol (1988) 1.04

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04